![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.
|
| Thread Tools | |
| Display Modes | |
|
|